MYGN Key Statistics, Chart & Performance
The current stock price of MYGN is 6.15 USD. In the past month the price decreased by -12.39%. In the past year, price decreased by -55.01%.
MYGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About MYGN
Company Profile
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Company Info
MYRIAD GENETICS INC
322 North 2200 West
Salt Lake City UTAH 84108 US
CEO: R. Bryan Riggsbee
Employees: 2700
Phone: 18015843600
MYRIAD GENETICS INC / MYGN FAQ
What does MYRIAD GENETICS INC do?
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
What is the stock price of MYRIAD GENETICS INC today?
The current stock price of MYGN is 6.15 USD. The price decreased by -0.32% in the last trading session.
Does MYRIAD GENETICS INC pay dividends?
MYGN does not pay a dividend.
How is the ChartMill rating for MYRIAD GENETICS INC?
MYGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of MYGN stock?
MYRIAD GENETICS INC (MYGN) has a market capitalization of 573.24M USD. This makes MYGN a Small Cap stock.
When does MYRIAD GENETICS INC (MYGN) report earnings?
MYRIAD GENETICS INC (MYGN) will report earnings on 2026-01-15, after the market close.
MYGN Technical Analysis
MYGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MYGN. MYGN has a bad profitability rating. Also its financial health evaluation is rather negative.
MYGN Financial Highlights
Over the last trailing twelve months MYGN reported a non-GAAP Earnings per Share(EPS) of 0.05. The EPS decreased by -64.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.01% | ||
| ROE | -107.43% | ||
| Debt/Equity | 0.32 |
MYGN Forecast & Estimates
19 analysts have analysed MYGN and the average price target is 8.22 USD. This implies a price increase of 33.74% is expected in the next year compared to the current price of 6.15.
For the next year, analysts expect an EPS growth of -93.22% and a revenue growth -2.03% for MYGN